Safety & Tolerability Assessment

Patient notes that she has not experienced any nausea since her first 2 weeks taking Orenitram, and has not experienced any new-onset side effects.

Study design

In a multicenter, prospective, real-world, observational ADAPT Registry study, adult patients with PAH were followed for up to 78 weeks after initiating oral trepostinil. Patient-reported incidence and treatment of common side effects were collected to better understand side effect management and tolerability.